Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond

Transfusion Medicine Reviews

Volumn 31, Issue 1, 2017, Pages 26-35

  Villa, Carlos H ^a   Cines, Douglas B ^b   Siegel, Don L ^b   Muzykantov, Vladimir ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Biocompatibility; Drug delivery; Immunogenicity; Pharmacokinetics; Red blood cells

Indexed keywords

DRUG CARRIER; HYBRID PROTEIN; TER119 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY FUSION PROTEIN; UNCLASSIFIED DRUG;

BIOCOMPATIBILITY; BLOOD TRANSFUSION; CELL ENGINEERING; CELL SURFACE; CHEMICAL MODIFICATION; CROSS LINKING; DRUG COATING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TARGETING; ENCAPSULATION; ERYTHROCYTE; HUMAN; IMMUNOGENICITY; LIGAND BINDING; NONHUMAN; REVIEW; PHYSIOLOGY; PROCEDURES;

BLOOD TRANSFUSION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ERYTHROCYTES; HUMANS;

EID: 84999791404     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2016.08.004     Document Type: Review

References (146)

1. [1] Turecek, PL, Bossard, MJ, Schoetens, F, Ivens, IA, PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci 105 (2016), 460–475.
2. [2] Jhaveri, A, Torchilin, V, Intracellular delivery of nanocarriers and targeting to subcellular organelles. Expert Opin Drug Deliv 13 (2016), 49–70.
3. [3] Sockolosky, JT, Szoka, FC, The neonatal fc receptor, FcRn, as a target for drug delivery and therapy. Adv Drug Deliv Rev 91 (2015), 109–124.
4. [4] Villa, CH, Anselmo, AC, Mitragotri, S, Muzykantov, V, Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems. Adv Drug Deliv Rev, 2016.
5. [5] Huang, B, Abraham, WD, Zheng, Y, Bustamante Lopez, SC, Luo, SS, Irvine, DJ, Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci Transl Med, 7, 2015, 291ra294.
6. [6] Pickens, B, Mao, Y, Li, D, Siegel, DL, Poncz, M, Cines, DB, et al. Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models. Blood 125 (2015), 3326–3334.
7. [7] Villa, CH, Pan, DC, Zaitsev, S, Cines, DB, Siegel, DL, Muzykantov, VR, Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier. Ther Deliv 6 (2015), 795–826.
8. [8] Sprandel, U, Way, JL, Erythrocytes as drug carriers in medicine. 2013, Springer Science & Business Media, Place Publisher.
9. [9] Whelihan, MF, Zachary, V, Orfeo, T, Mann, KG, Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood 120 (2012), 3837–3845.
10. [10] Odera, M, Otieno, W, Adhiambo, C, Stoute, JA, Dual role of erythrocyte complement receptor type 1 in immune complex-mediated macrophage stimulation: implications for the pathogenesis of Plasmodium falciparum malaria. Clin Exp Immunol 166 (2011), 201–207.
11. [11] Davies, KA, Hird, V, Stewart, S, Sivolapenko, GB, Jose, P, Epenetos, AA, et al. A study of in vivo immune complex formation and clearance in man. J Immunol 144 (1990), 4613–4620.
12. [12] Coller, BS, Springer, KT, Beer, JH, Mohandas, N, Scudder, LE, Norton, KJ, et al. Thromboerythrocytes. In vitro studies of a potential autologous, semi-artificial alternative to platelet transfusions. J Clin Invest 89 (1992), 546–555.
13. [13] Kuhn, SE, Nardin, A, Klebba, PE, Taylor, RP, Escherichia coli bound to the primate erythrocyte complement receptor via bispecific monoclonal antibodies are transferred to and phagocytosed by human monocytes in an in vitro model. J Immunol 160 (1998), 5088–5097.
14. [14] Gyimesi, E, Bankovich, AJ, Schuman, TA, Goldberg, JB, Lindorfer, MA, Taylor, RP, Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunol Lett 95 (2004), 185–192.
15. [15] Hahn, CS, French, OG, Foley, P, Martin, EN, Taylor, RP, Bispecific monoclonal antibodies mediate binding of dengue virus to erythrocytes in a monkey model of passive viremia. J Immunol 166 (2001), 1057–1065.
16. [16] Sharma, R, Zhao, H, Al-Saleem, FH, Ubaid, AS, Puligedda, RD, Segan, AT, et al. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor. Mol Immunol 57 (2014), 247–254.
17. [17] Muzykantov, VR, Taylor, RP, Attachment of biotinylated antibody to red blood cells: antigen-binding capacity of immunoerythrocytes and their susceptibility to lysis by complement. Anal Biochem 223 (1994), 142–148.
18. [18] Ferguson, PJ, Reist, CJ, Martin, EN, Johnson, C, Greene, KL, Kuhn, S, et al. Antigen-based heteropolymers. A potential therapy for binding and clearing autoantibodies via erythrocyte CR1. Arthritis Rheum 38 (1995), 190–200.
19. [19] Mukthavaram, R, Shi, G, Kesari, S, Simberg, D, Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. J Control Release 183 (2014), 146–153.
20. [20] Anselmo, AC, Gupta, V, Zern, BJ, Pan, D, Zakrewsky, M, Muzykantov, V, et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 7 (2013), 11129–11137.
21. [21] Kooyman, DL, Byrne, GW, McClellan, S, Nielsen, D, Tone, M, Waldmann, H, et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 269 (1995), 89–92.
22. [22] Atukorale, PU, Yang, YS, Bekdemir, A, Carney, RP, Silva, PJ, Watson, N, et al. Influence of the glycocalyx and plasma membrane composition on amphiphilic gold nanoparticle association with erythrocytes. Nanoscale 7 (2015), 11420–11432.
23. [23] Dale, GL, Kuhl, W, Beutler, E, Incorporation of glucocerebrosidase into Gaucher's disease monocytes in vitro. Proc Natl Acad Sci U S A 76 (1979), 473–475.
24. [24] Magnani, M, Erythrocytes as carriers for drugs: the transition from the laboratory to the clinic is approaching. Expert Opin Biol Ther 12 (2012), 137–138.
25. [25] Hamidi, M, Zarrin, A, Foroozesh, M, Mohammadi-Samani, S, Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release 118 (2007), 145–160.
26. [26] Rossi, L, Serafini, S, Pierige, F, Antonelli, A, Cerasi, A, Fraternale, A, et al. Erythrocyte-based drug delivery. Expert Opin Drug Deliv 2 (2005), 311–322.
27. [27] Ihler, GM, Glew, RH, Schnure, FW, Enzyme loading of erythrocytes. Proc Natl Acad Sci U S A 70 (1973), 2663–2666.
28. [28] Bax, BE, Bain, MD, Fairbanks, LD, Webster, AD, Chalmers, RA, In vitro and in vivo studies with human carrier erythrocytes loaded with polyethylene glycol-conjugated and native adenosine deaminase. Br J Haematol 109 (2000), 549–554.
29. [29] Rossi, L, Serafini, S, Cappellacci, L, Balestra, E, Brandi, G, Schiavano, GF, et al. Erythrocyte-mediated delivery of a new homodinucleotide active against human immunodeficiency virus and herpes simplex virus. J Antimicrob Chemother 47 (2001), 819–827.
30. [30] Banz, A, Cremel, M, Rembert, A, Godfrin, Y, In situ targeting of dendritic cells by antigen-loaded red blood cells: a novel approach to cancer immunotherapy. Vaccine 28 (2010), 2965–2972.
31. [31] Magnani, M, Chiarantini, L, Mancini, U, Rossi, L, Vittoria, E, Fazi, A, Red blood cells as an antigen-delivery system. Biotechnol Appl Biochem 16 (1992), 188–194.
32. [32] Bossa, F, Latiano, A, Rossi, L, Magnani, M, Palmieri, O, Dallapiccola, B, et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am J Gastroenterol 103 (2008), 2509–2516.
33. [33] Rossi, L, Serafini, S, Cenerini, L, Picardi, F, Bigi, L, Panzani, I, et al. Erythrocyte-mediated delivery of dexamethasone in patients with chronic obstructive pulmonary disease. Biotechnol Appl Biochem 33 (2001), 85–89.
34. [34] Godfrin, Y, Bax, B, Enzyme bioreactors as drugs. Drugs Future 37 (2012), 263–272.
35. [35] Domenech, C, Thomas, X, Chabaud, S, Baruchel, A, Gueyffier, F, Mazingue, F, et al. L-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial. Br J Haematol 153 (2011), 58–65.
36. [36] Godfrin, Y, Horand, F, Franco, R, Dufour, E, Kosenko, E, Bax, BE, et al. International seminar on the red blood cells as vehicles for drugs. Expert Opin Biol Ther 12 (2012), 127–133.
37. [37] Bax, BE, Bain, MD, Fairbanks, LD, Webster, AD, Ind, PW, Hershfield, MS, et al. A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency. Eur J Haematol 79 (2007), 338–348.
38. [38] Pierige, F, Serafini, S, Rossi, L, Magnani, M, Cell-based drug delivery. Adv Drug Deliv Rev 60 (2008), 286–295.
39. [39] Bax, BE, Bain, MD, Scarpelli, M, Filosto, M, Tonin, P, Moran, N, Clinical and biochemical improvements in a patient with MNGIE following enzyme replacement. Neurology 81 (2013), 1269–1271.
40. [40] Krantz, A, Red cell-mediated therapy: opportunities and challenges. Blood Cells Mol Dis 23 (1997), 58–68.
41. [41] Patel, PD, Dand, N, Hirlekar, RS, Kadam, VJ, Drug loaded erythrocytes: as novel drug delivery system. Curr Pharm Des 14 (2008), 63–70.
42. [42] Rossi, L, Serafini, S, Pierige, F, Castro, M, Ambrosini, MI, Knafelz, D, et al. Erythrocytes as a controlled drug delivery system: clinical evidences. J Control Release 116 (2006), e43–e45.
43. [43] Pérez, MT, Alvarez, FJ, García-Pérez, AI, Lucas, L, Tejedor, MC, Sancho, P, Heterogeneity of hypotonically loaded rat erythrocyte populations as detected by counter-current distribution in aqueous polymer two-phase systems. J Chromatogr B Biomed Appl 677 (1996), 45–51.
44. [44] Alvarez, FJ, Herraez, A, Murciano, JC, Jordan, JA, Diez, JC, Tejedor, MC, In vivo survival and organ uptake of loaded carrier rat erythrocytes. J Biochem 120 (1996), 286–291.
45. [45] Ktavtzoff, R, Desbois, I, Doinel, C, Colombat, P, Lamagnere, JP, Chassaigne, M, et al. Immunological response to L-asparaginase loaded into red blood cells. Adv Exp Med Biol 326 (1992), 175–182.
46. [46] Tonetti, M, Astroff, B, Satterfield, W, De Flora, A, Benatti, U, DeLoach, JR, Construction and characterization of adriamycin-loaded canine red blood cells as a potential slow delivery system. Biotechnol Appl Biochem 12 (1990), 621–629.
47. 2 release by inositol hexaphosphate-loaded erythrocytes. Proc Natl Acad Sci U S A 84 (1987), 6894–6898.
48. [48] Hambye, AS, Verbeke, KA, Vandermeiren, RP, Joosens, EJ, Verbruggen, AM, De Roo, MJ, Comparison of modified technetium-99m albumin and technetium-99m red blood cells for equilibrium ventriculography. J Nucl Med 38 (1997), 1521–1528.
49. [49] Kravtzoff, R, Colombat, PH, Desbois, I, Linassier, C, Muh, JP, Philip, T, et al. Tolerance evaluation of L-asparaginase loaded in red blood cells. Eur J Clin Pharmacol 51 (1996), 221–225.
50. [50] Kravtzoff, R, Desbois, I, Lamagnere, JP, Muh, JP, Valat, C, Chassaigne, M, et al. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells. Eur J Clin Pharmacol 49 (1996), 465–470.
51. [51] Chessa, L, Leuzzi, V, Plebani, A, Soresina, A, Micheli, R, D'Agnano, D, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis, 9, 2014, 5.
52. [52] Muzykantov, VR, Zaltsman, AB, Smirnov, MD, Samokhin, GP, Morgan, BP, Target-sensitive immunoerythrocytes: interaction of biotinylated red blood cells with immobilized avidin induces their lysis by complement. Biochim Biophys Acta 1279 (1996), 137–143.
53. [53] Magnani, M, Mancini, U, Bianchi, M, Fazi, A, Comparison of uricase-bound and uricase-loaded erythrocytes as bioreactors for uric acid degradation. Adv Exp Med Biol 326 (1992), 189–194.
54. [54] Bayer, EA, Safars, M, Wilchek, M, Selective labeling of sulfhydryls and disulfides on blot transfers using avidin-biotin technology: studies on purified proteins and erythrocyte membranes. Anal Biochem 161 (1987), 262–271.
55. [55] Muzykantov, VR, Sakharov, DV, Domogatsky, SP, Goncharov, NV, Danilov, SM, Directed targeting of immunoerythrocytes provides local protection of endothelial cells from damage by hydrogen peroxide. Am J Pathol 128 (1987), 276–285.
56. [56] Wilchek, M, Ben-Hur, H, Bayer, EA, P-Diazobenzoyl biocytin—a new biotinylating reagent for the labeling of tyrosines and histidines in proteins. Biochem Biophys Res Commun 138 (1986), 872–879.
57. [57] Shi, G, Mukthavaram, R, Kesari, S, Simberg, D, Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo. Adv Healthc Mater 3 (2014), 142–148.
58. [58] Chiarantini, L, Droleskey, R, Magnani, M, DeLoach, JR, In vitro targeting of erythrocytes to cytotoxic T-cells by coupling of Thy-1.2 monoclonal antibody. Biotechnol Appl Biochem 15 (1992), 171–184.
59. [59] Smirnov, VN, Domogatsky, SP, Dolgov, VV, Hvatov, VB, Klibanov, AL, Koteliansky, VE, et al. Carrier-directed targeting of liposomes and erythrocytes to denuded areas of vessel wall. Proc Natl Acad Sci U S A 83 (1986), 6603–6607.
60. [60] Muzykantov, VR, Smirnov, MD, Samokhin, GP, Avidin acylation prevents the complement-dependent lysis of avidin-carrying erythrocytes. Biochem J 273:Pt 2 (1991), 393–397.
61. [61] Muzykantov, VR, Seregina, N, Smirnov, MD, Fast lysis by complement and uptake by liver of avidin-carrying biotinylated erythrocytes. Int J Artif Organs 15 (1992), 622–627.
62. [62] Muzykantov, VR, Smirnov, MD, Samokhin, GP, Streptavidin-induced lysis of homologous biotinylated erythrocytes. Evidence against the key role of the avidin charge in complement activation via the alternative pathway. FEBS Lett 280 (1991), 112–114.
63. [63] Muzykantov, VR, Murciano, JC, Attachment of antibody to biotinylated red blood cells: immuno-red blood cells display high affinity to immobilized antigen and normal biodistribution in rats. Biotechnol Appl Biochem 24 (1996), 41–45.
64. [64] Muzykantov, VR, Smirnov, MD, Klibanov, AL, Avidin attachment to red blood cells via a phospholipid derivative of biotin provides complement-resistant immunoerythrocytes. J Immunol Methods 158 (1993), 183–190.
65. [65] Müller, M, Büchi, L, Woodtli, K, Haeberli, A, Beer, JH, Preparation and characterization of ‘heparinocytes’: erythrocytes with covalently bound low molecular weight heparin. FEBS Lett 468 (2000), 115–119.
66. [66] Muzykantov, VR, Sakharov, DV, Smirnov, MD, Samokhin, GP, Smirnov, VN, Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot. Biochim Biophys Acta 884 (1986), 355–362.
67. [67] Ganguly, K, Krasik, T, Medinilla, S, Bdeir, K, Cines, DB, Muzykantov, VR, et al. Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther 312 (2005), 1106–1113.
68. [68] Murciano, JC, Higazi, AA, Cines, DB, Muzykantov, VR, Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile. J Control Release 139 (2009), 190–196.
69. [69] Murciano, JC, Medinilla, S, Eslin, D, Atochina, E, Cines, DB, Muzykantov, VR, Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol 21 (2003), 891–896.
70. [70] Villa, CH, Muzykantov, VR, Cines, DB, The emerging role for red blood cells in haemostasis: opportunity for intervention. ISBT Sci Ser 11 (2016), 158–164.
71. [71] Armstead, WM, Christine, AJ, Higazi, AA, Cines, DB, Urokinase plasminogen activator impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK. J Neurotrauma 25 (2008), 1375–1381.
72. [72] Armstead, WM, Cines, DB, Higazi, AA, Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke 36 (2005), 2265–2269.
73. [73] Armstead, WM, Ganguly, K, Riley, J, Kiessling, JW, Cines, DB, Higazi, AA, et al. Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun–N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the newborn pig. Pediatr Crit Care Med 12 (2011), e369–e375.
74. [74] Danielyan, K, Ganguly, K, Ding, BS, Atochin, D, Zaitsev, S, Murciano, JC, et al. Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation 118 (2008), 1442–1449.
75. [75] Armstead, WM, Ganguly, K, Kiessling, JW, Chen, XH, Smith, DH, Higazi, AA, et al. Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation. J Cereb Blood Flow Metab 29 (2009), 1463–1474.
76. [76] Taylor, RP, Sutherland, WM, Reist, CJ, Webb, DJ, Wright, EL, Labuguen, RH, Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment. Proc Natl Acad Sci U S A 88 (1991), 3305–3309.
77. [77] Zaitsev, S, Danielyan, K, Murciano, JC, Ganguly, K, Krasik, T, Taylor, RP, et al. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood 108 (2006), 1895–1902.
78. [78] Spitzer, D, Unsinger, J, Bessler, M, Atkinson, JP, ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement. Mol Immunol 40 (2004), 911–919.
79. [79] Ding, BS, Gottstein, C, Grunow, A, Kuo, A, Ganguly, K, Albelda, SM, et al. Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature. Blood 106 (2005), 4191–4198.
80. [80] Oudin, S, Libyh, MT, Goossens, D, Dervillez, X, Philbert, F, Reveil, B, et al. A soluble recombinant multimeric anti-Rh(D) single-chain Fv/CR1 molecule restores the immune complex binding ability of CR1-deficient erythrocytes. J Immunol 164 (2000), 1505–1513.
81. [81] Kina, T, Ikuta, K, Takayama, E, Wada, K, Majumdar, AS, Weissman, IL, et al. The monoclonal antibody TER-119 recognizes a molecule associated with glycophorin A and specifically marks the late stages of murine erythroid lineage. Br J Haematol 109 (2000), 280–287.
82. [82] Spitzer, D, Unsinger, J, Mao, D, Atkinson, JP, Spitzer, D, Molina, H, et al. In vivo correction of complement regulatory protein deficiency with an inhibitor targeting the red blood cell membrane. J Immunol 175 (2005), 7763–7770.
83. [83] Spitzer, D, Wu, X, Ma, X, Xu, L, Ponder, KP, Atkinson, JP, Cutting edge: treatment of complement regulatory protein deficiency by retroviral in vivo gene therapy. J Immunol 177 (2006), 4953–4956.
84. [84] Zaitsev, S, Spitzer, D, Murciano, JC, Ding, BS, Tliba, S, Kowalska, MA, et al. Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther 332 (2010), 1022–1031.
85. [85] Zaitsev, S, Spitzer, D, Murciano, JC, Ding, BS, Tliba, S, Kowalska, MA, et al. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood 115 (2010), 5241–5248.
86. [86] Zaitsev, S, Kowalska, MA, Neyman, M, Carnemolla, R, Tliba, S, Ding, BS, et al. Targeting recombinant thrombomodulin fusion protein to red blood cells provides multifaceted thromboprophylaxis. Blood 119 (2012), 4779–4785.
87. [87] Burton, NM, Bruce, LJ, Modelling the structure of the red cell membrane. Biochem Cell Biol 89 (2011), 200–215.
88. [88] Taylor, RP, Sutherland, WM, Martin, EN, Ferguson, PJ, Reinagel, ML, Gilbert, E, et al. Bispecific monoclonal antibody complexes bound to primate erythrocyte complement receptor 1 facilitate virus clearance in a monkey model. J Immunol 158 (1997), 842–850.
89. [89] Repik, A, Pincus, SE, Ghiran, I, Nicholson-Weller, A, Asher, DR, Cerny, AM, et al. A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1). Clin Exp Immunol 140 (2005), 230–240.
90. [90] Reist, CJ, Liang, HY, Denny, D, Martin, EN, Scheld, WM, Taylor, RP, Cross-linked bispecific monoclonal antibody heteropolymers facilitate the clearance of human IgM from the circulation of squirrel monkeys. Eur J Immunol 24 (1994), 2018–2025.
91. [91] Taylor, RP, Martin, EN, Reinagel, ML, Nardin, A, Craig, M, Choice, Q, et al. Bispecific monoclonal antibody complexes facilitate erythrocyte binding and liver clearance of a prototype particulate pathogen in a monkey model. J Immunol 159 (1997), 4035–4044.
92. [92] Kontos, S, Hubbell, JA, Improving protein pharmacokinetics by engineering erythrocyte affinity. Mol Pharm 7 (2010), 2141–2147.
93. [93] Sahoo, K, Koralege, RS, Flynn, N, Koteeswaran, S, Clark, P, Hartson, S, et al. Nanoparticle attachment to erythrocyte via the glycophorin a targeted ERY1 ligand enhances binding without impacting cellular function. Pharm Res 33 (2016), 1191–1203.
94. [94] Paulitschke, M, Nash, GB, Anstee, DJ, Tanner, MJ, Gratzer, WB, Perturbation of red blood cell membrane rigidity by extracellular ligands. Blood 86 (1995), 342–348.
95. [95] Gallagher, PG, Chang, SH, Rettig, MP, Neely, JE, Hillery, CA, Smith, BD, et al. Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 101 (2003), 4625–4627.
96. [96] Oldenborg, PA, Zheleznyak, A, Fang, YF, Lagenaur, CF, Gresham, HD, Lindberg, FP, Role of CD47 as a marker of self on red blood cells. Science 288 (2000), 2051–2054.
97. [97] Chasis, JA, Mohandas, N, Shohet, SB, Erythrocyte membrane rigidity induced by glycophorin A–ligand interaction. Evidence for a ligand-induced association between glycophorin A and skeletal proteins. J Clin Invest 75 (1985), 1919–1926.
98. [98] Glodek, AM, Mirchev, R, Golan, DE, Khoory, JA, Burns, JM, Shevkoplyas, SS, et al. Ligation of complement receptor 1 increases erythrocyte membrane deformability. Blood 116 (2010), 6063–6071.
99. [99] Sticher, B, Giger, U, Naef, R, Burger, R, Lutz, HU, Naturally occurring human anti-band 3 autoantibodies accelerate clearance of erythrocytes in guinea pigs. Blood, 85, 1995.
100. [100] Khoory, J, Estanislau, J, Elkhal, A, Lazaar, A, Melhorn, MI, Brodsky, A, et al. Ligation of glycophorin a generates reactive oxygen species leading to decreased red blood cell function. PLoS One, 11, 2016, e0141206.
101. [101] Aleman, MM, Walton, BL, Byrnes, JR, Wolberg, AS, Fibrinogen and red blood cells in venous thrombosis. Thromb Res 133:Suppl. 1 (2014), S38–S40.
102. [102] Aarts, PA, Heethaar, RM, Sixma, JJ, Red blood cell deformability influences platelets—vessel wall interaction in flowing blood. Blood 64 (1984), 1228–1233.
103. [103] Willekens, FL, Werre, JM, Groenen-Dopp, YA, Roerdinkholder-Stoelwinder, B, de Pauw, B, Bosman, GJ, Erythrocyte vesiculation: a self-protective mechanism?. Br J Haematol 141 (2008), 549–556.
104. [104] Koshiar, RL, Somajo, S, Norstrom, E, Dahlback, B, Erythrocyte-derived microparticles supporting activated protein C–mediated regulation of blood coagulation. PLoS One, 9, 2014, e104200.
105. [105] Zecher, D, Cumpelik, A, Schifferli, JA, Erythrocyte-derived microvesicles amplify systemic inflammation by thrombin-dependent activation of complement. Arterioscler Thromb Vasc Biol 34 (2014), 313–320.
106. [106] Camus, SM, De Moraes, JA, Bonnin, P, Abbyad, P, Le Jeune, S, Lionnet, F, et al. Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease. Blood 125 (2015), 3805–3814.
107. [107] Peyrou, V, Lormeau, JC, Herault, JP, Gaich, C, Pfliegger, AM, Herbert, JM, Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost 81 (1999), 400–406.
108. [108] Closse, C, Dachary-Prigent, J, Boisseau, MR, Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 107 (1999), 300–302.
109. [109] Figueiredo, RT, Fernandez, PL, Mourao-Sa, DS, Porto, BN, Dutra, FF, Alves, LS, et al. Characterization of heme as activator of toll-like receptor 4. J Biol Chem 282 (2007), 20221–20229.
110. [110] Pasvol, G, Chasis, JA, Mohandas, N, Anstee, DJ, Tanner, MJ, Merry, AH, Inhibition of malarial parasite invasion by monoclonal antibodies against glycophorin A correlates with reduction in red cell membrane deformability. Blood 74 (1989), 1836–1843.
111. [111] Olsson, ML, Clausen, H, Modifying the red cell surface: towards an ABO-universal blood supply. Br J Haematol 140 (2008), 3–12.
112. [112] Garratty, G, Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf 11 (2012), 635–642.
113. [113] Arndt, PA, Leger, RM, Garratty, G, Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion 52 (2012), 602–612.
114. [114] Crookston, KP, Reiner, AP, Cooper, LJ, Sacher, RA, Blajchman, MA, Heddle, NM, RBC T activation and hemolysis: implications for pediatric transfusion management. Transfusion 40 (2000), 801–812.
115. [115] Heddle, NM, Soutar, RL, O'Hoski, PL, Singer, J, McBride, JA, Ali, MA, et al. A prospective study to determine the frequency and clinical significance of alloimmunization post-transfusion. Br J Haematol 91 (1995), 1000–1005.
116. [116] Zimring, JC, Stowell, SR, Johnsen, JM, Hendrickson, JE, Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: current paradigms and future considerations. Transfus Clin Biol 19 (2012), 125–131.
117. [117] Ryder, AB, Zimring, JC, Hendrickson, JE, Factors influencing RBC alloimmunization: lessons learned from murine models. Transfus Med Hemother 41 (2014), 406–419.
118. [118] Smith, NH, Henry, KL, Cadwell, CM, Bennett, A, Hendrickson, JE, Frame, T, et al. Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion 52 (2012), 2620–2630.
119. [119] Girard-Pierce, KR, Stowell, SR, Smith, NH, Arthur, CM, Sullivan, HC, Hendrickson, JE, et al. A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. Blood 122 (2013), 1793–1801.
120. [120] Liepkalns, JS, Cadwell, CM, Stowell, SR, Hod, EA, Spitalnik, SL, Zimring, JC, Resistance of a subset of red blood cells to clearance by antibodies in a mouse model of incompatible transfusion. Transfusion 53 (2013), 1319–1327.
121. [121] Hudson, KE, Hendrickson, JE, Cadwell, CM, Iwakoshi, NN, Zimring, JC, Partial tolerance of autoreactive B and T cells to erythrocyte-specific self-antigens in mice. Haematologica 97 (2012), 1836–1844.
122. [122] Kontos, S, Kourtis, IC, Dane, KY, Hubbell, JA, Engineering antigens for in situ erythrocyte binding induces T-cell deletion. Proc Natl Acad Sci U S A 110 (2013), E60–E68.
123. [123] Lorentz, KM, Kontos, S, Diaceri, G, Henry, H, Hubbell, JA, Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase. Sci Adv, 1, 2015, e1500112.
124. [124] Grimm, AJ, Kontos, S, Diaceri, G, Quaglia-Thermes, X, Hubbell, JA, Memory of tolerance and induction of regulatory T cells by erythrocyte-targeted antigens. Sci Rep, 5, 2015, 15907.
125. [125] Murray, AM, Pearson, IF, Fairbanks, LD, Chalmers, RA, Bain, MD, Bax, BE, The mouse immune response to carrier erythrocyte entrapped antigens. Vaccine 24 (2006), 6129–6139.
126. [126] Smith, NH, Hod, EA, Spitalnik, SL, Zimring, JC, Hendrickson, JE, Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood 119 (2012), 1566–1569.
127. [127] Richards, AL, Hendrickson, JE, Zimring, JC, Hudson, KE, Erythrophagocytosis by plasmacytoid dendritic cells and monocytes is enhanced during inflammation. Transfusion 56 (2016), 905–916.
128. [128] Gersh, KC, Zaitsev, S, Cines, DB, Muzykantov, V, Weisel, JW, Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent. Blood 117 (2011), 4964–4967.
129. [129] Gersh, KC, Zaitsev, S, Muzykantov, V, Cines, DB, Weisel, JW, The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics. J Thromb Haemost 8 (2010), 1066–1074.
130. [130] Bosman, GJ, Survival of red blood cells after transfusion: processes and consequences. Front Physiol, 4, 2013, 376.
131. [131] Luten, M, Roerdinkholder-Stoelwinder, B, Schaap, NP, de Grip, WJ, Bos, HJ, Bosman, GJ, Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. Transfusion 48 (2008), 1478–1485.
132. [132] Sparrow, RL, Time to revisit red blood cell additive solutions and storage conditions: a role for “omics” analyses. Blood Transfus 10:Suppl. 2 (2012), s7–11.
133. [133] Alley, SC, Okeley, NM, Senter, PD, Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14 (2010), 529–537.
134. [134] Aabb, Standards for perioperative autologous blood collection and adminstration, 6th edition. 2014, American Association of Blood Banks (AABB), Place Published: USA.
135. [135] Tabibian, JH, Wong Kee Song, LM, Enders, FB, Aguet, JC, Tabibian, N, Technetium-labeled erythrocyte scintigraphy in acute gastrointestinal bleeding. Int J Colorectal Dis 28 (2013), 1099–1105.
136. [136] U.S.F.a.D. Administration, Blood and blood products. http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/, 2014.
137. [137] Shi, J, Kundrat, L, Pishesha, N, Bilate, A, Theile, C, Maruyama, T, et al. Engineered red blood cells as carriers for systemic delivery of a wide array of functional probes. Proc Natl Acad Sci U S A 111 (2014), 10131–10136.
138. [138] Giarratana, MC, Rouard, H, Dumont, A, Kiger, L, Safeukui, I, Le Pennec, PY, et al. Proof of principle for transfusion of in vitro-generated red blood cells. Blood 118 (2011), 5071–5079.
139. [139] Risbano, MG, Kanias, T, Triulzi, D, Donadee, C, Barge, S, Badlam, J, et al. Effects of aged stored autologous red blood cells on human endothelial function. Am J Respir Crit Care Med 192 (2015), 1223–1233.
140. [140] Hod, EA, Spitalnik, SL, Harmful effects of transfusion of older stored red blood cells: iron and inflammation. Transfusion 51 (2011), 881–885.
141. [141] Zimring, JC, Established and theoretical factors to consider in assessing the red cell storage lesion. Blood 125 (2015), 2185–2190.
142. [142] Cluitmans, JC, Hardeman, MR, Dinkla, S, Brock, R, Bosman, GJ, Red blood cell deformability during storage: towards functional proteomics and metabolomics in the Blood Bank. Blood Transfus 10:Suppl. 2 (2012), s12–s18.
143. [143] Fergusson, DA, Hebert, P, Hogan, DL, LeBel, L, Rouvinez-Bouali, N, Smyth, JA, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA 308 (2012), 1443–1451.
144. [144] Steiner, ME, Ness, PM, Assmann, SF, Triulzi, DJ, Sloan, SR, Delaney, M, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med 372 (2015), 1419–1429.
145. [145] Dhabangi, A, Ainomugisha, B, Cserti-Gazdewich, C, Ddungu, H, Kyeyune, D, Musisi, E, et al. Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial. JAMA 314 (2015), 2514–2523.
146. [146] Lacroix, J, Hebert, PC, Fergusson, DA, Tinmouth, A, Cook, DJ, Marshall, JC, et al. Age of transfused blood in critically ill adults. N Engl J Med 372 (2015), 1410–1418.